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Eric K. Peden, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: Endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is common and effective
in the well-selected patient. Hypertension is a common indication for intervention and a major component of metabolic
syndrome (MetS). The impact of MetS on outcomes after percutaneous renal intervention is unknown.
Methods: We performed a retrospective analysis of records from patients who underwent endovascular intervention for
ARAS and were followed by duplex ultrasound between January 1990 and January 2008. MetS was defined as the
presence of >3 of the following criteria: Blood pressure >140 mm Hg/>90 mm Hg; triglycerides >150 mg/dL;
high-density lipoprotein<50 mg/dL for women and<40 mg/dL for men; fasting blood glucose>110 mg/dL; or body
mass index >30 kg/m2. The average follow-up period was 3.3 years. Clinical benefit defined as freedom from
renal-related morbidity (increase in persistent creatinine >20% of baseline, progression to hemodialysis, death from
renal-related causes) or freedom from recurrent hypertension, anatomic patency, restenosis, and patient survival were
measured.
Results: Five hundred ninety-two renal artery interventions were performed in 427 patients. Fifty-two percent were
identified as having MetS. Patients with MetS were more often female (35% vs 50%, NoMetS vs MetS). There were no
significant differences in presenting symptoms. There was no peri-operative mortality and equivalent morbidity (6% vs
7%, NoMetS vsMetS). Patients withMetS had equivalent survival and cumulative patency. However, theMetS group had
a lower five-year freedom from restenosis (872% vs 699%, NoMetS vs MetS; P < .01) and lower five-year retained
clinical benefit (718% vs 458%, NoMetS vs MetS; P < .01) with a higher number progressing to hemodialysis (3% vs
13%, NoMetS vs MetS; P < .01). Individually, the components of MetS did not influence outcomes. Statin therapy did
not influence outcomes.
Conclusion: MetS is associated with markedly reduced renal clinical benefit and increased progression to hemodialysis
following endovascular intervention for atherosclerotic renal artery stenosis. MetS is thus a risk factor for poor long-term
outcomes following renal interventions. ( J Vasc Surg 2010;51:926-32.)Endovascular therapy for symptomatic atherosclerotic
renal artery stenosis has increased in frequency and is effec-
tive in controlling blood pressure and reversing declining
renal function in the well-selected patient.1 The greatest
efficacy appears to be in the hypertensive patient with a
distinct lesion or the patient with rapidly decreasing esti-
mated glomerular filtration rate and no evidence of paren-
chymal damage.1,2 Metabolic syndrome (MetS) is a condi-
tion manifested by hypertension, obesity, and a prediabetic
state (high fasting blood glucose, high triglycerides, and
low high-density lipoproteins), is rapidly increasing in prev-
alence3 and is an emerging risk factor for cardiovascular
morbidity and mortality.4 It is known that the presence of
MetS is a marker for progression of chronic renal insuffi-
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926ciency.5 MetS is associated with a larger coronary infarct
size, severe heart failure, and higher overall in-hospital
complications, including acute renal failure.6,7 MetS has
also been demonstrated to amplify vascular wall thick-
ness and stiffness8 and create an overall pro-thrombotic
state.9 Patients with MetS exhibit impaired fibrinolysis
through increased plasminogen activator-1 levels com-
pared with those withoutMetS.10 Prior studies have shown
that the presence of MetS can be correlated with increased
carotid intima-media thickness in both men11 and women,12
that peripheral arterial disease will be present in 23% of
the patients, and that female patients with the combina-
tion of MetS and peripheral arterial disease are more
likely to have a trend toward kidney dysfunction.13 We
have recently demonstrated that the presence of MetS is a
risk factor for stroke following carotid intervention (endar-
terectomy or stent).14 The purpose of this study is to
examine the impact of MetS on outcomes after percutane-
ous renal intervention, which is often used in the setting of
poorly controlled hypertension and decreasing renal func-
tion. The hypothesis we wish to test is that the presence of
MetS is associated with poor renal outcomes after percuta-
neous intervention.
METHODS
Study design. We performed a retrospective analysis
of records from patients who underwent percutaneous
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erosclerotic renal artery stenosis of the main renal artery
between January 1990 and December 2008. MetS was
defined as previously described.15 We substituted a body
mass index (BMI) score30.0 as a positive score instead of
an abdominal circumference102 cm or88 cm for male
or female patients, respectively.14 Indications for interven-
tion were poorly controlled hypertension (diastolic BP90
mmHg on3 antihypertensive medications) and/or with
elevated creatinine (1.5 mg/dL). For each patient, de-
mographics, existing comorbid conditions, and risk factors
for atherosclerosis were identified. Freedom from recurrent
hypertension, retained clinical benefit defined as freedom
from renal-related morbidity (increase in persistent creati-
nine 20% of baseline, progression to hemodialysis, death
from renal-related causes), and factors influencing these
parameters were measured. Average follow-up was 3.3
years (range, 1-14 years). Data utilization fell under the
category of secondary use of pre-existing data as defined by
the Institutional Review Board (IRB) and the Health In-
surance Portability and Accountability Act (HIPAA).
Treatment algorithm. Patients with hypertension or
elevated creatinine underwent a diagnostic study to identify
the presence of renal artery stenosis. This study consisted of
standard angiography, magnetic resonance angiography,
renal isotope scan, or duplex ultrasound. Duplex ultra-
sound criteria to identify renal artery stenosis have been
previously described.16-18 In the presence of clinical criteria
defined by Rundback et al19 and a 60% stenosis on
ultrasound or magnetic resonance angiography or a posi-
tive renal scan, angiography was performed. The majority
of these interventions were transfemoral, and no distal
protection devices were used. Patients not categorized into
the clinical criteria referenced were managed medically.
Occluded renal arteries and nonfunctioning kidneys were
not treated. Patients with creatinine 1.5 mg/mL were
hydrated overnight with normal saline, and those treated
within the last 5 years received mucomyst 600 mg twice a
day orally 24 hours preoperatively and 48 hours postoper-
atively. Patients were followed at 6-month intervals after
the procedure. Blood pressure, serum creatinine, and num-
ber of antihypertensive medications were identified during
these intervals. Each patient had at least one duplex ultra-
sound within 6 months of the procedure and an ultrasound
every 6 months thereafter to assess patency. If the duplex
ultrasound showed 60% stenosis and the patient had
recurrent symptoms, angiography was performed, and re-
stenosis was treated if the arterial diameter was decreased by
50%.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, congestive
heart disease, or prior coronary artery revascularizations. Ce-
rebrovascular disease included a history of stroke, transient
ischemic attack, or carotid artery revascularization. Hyper-
cholesterolemia was defined as fasting cholesterol 200
mg/dL. Diabetes was defined as a fasting plasma glucose
110 mg/dL or an HbA1c 7%. Diabetics were charac-
terized as IDDM (insulin-dependent diabetes mellitus) orNIDDM (non-insulin-dependent diabetes mellitus). Hy-
pertension was defined as diastolic blood pressure greater
than 90 mm Hg on 3 antihypertensive medications. An
elevated creatinine level was defined as 1.5 mg/dL on
two consecutive values during a three-month period.
Chronic renal insufficiency was defined as a persistent se-
rum creatinine 1.5 mg/dL for greater than 6 months.
eGFR was defined as 186.3  serum creatinine1.154 
age0.203  0.742 (if female)  1.212 (if African American).
The baseline serum creatinine was the value recorded clos-
est to the procedure. Patients were considered to have a
“nonfunctioning kidney” if any two of the following local
criteria used at our institution over the time of the study
were met: (1) a duplex ultrasound scan identified a pole-
to-pole length of less than 9 cm with no renal flow in the
main renal artery and parenchymal peak systolic velocity
10 cm/s; (2) surgically or congenitally absent kidney; (3)
no visible nephrogram on contrast arteriogram. A normal
contralateral kidney was considered a kidney without evi-
dence of 50% renal artery stenosis and not fulfilling
criteria for a “nonfunctioning kidney”. Renal resistive index
was defined from duplex imaging as 1-[EDV/PSV]*100.
Nephrosclerosis was defined as grade 1: Normal intrarenal
vessels, orderly progression of branching patterns (no prun-
ing), normal nephrogram with distinct corticomedullary
junction; grade 2: ectasia of arcuate and distal interlob-
ular arteries, peripheral pruning, reduced arterial volume
with normal renal mass, normal nephrogram; grade 3:
marked ectasia extending centrally, total pruning with
abrupt interlobar artery terminations, marked reduced ar-
terial volume with decreased renal mass, faint absent
nephrogram. An endoluminal procedural success was a
residual stenosis of 30%; failures were residual stenosis
30%, by angiographic measurement, including lesions
unable to be dilated or crossed and occlusion within 30
days. A death within 30 days of the procedure was consid-
ered procedure-related. Acute functional renal injury was
defined as a persistent increase in the serum creatinine of
0.5 mg/dL at 1 month after the procedure. Acute ana-
tomic renal injury was defined renal artery dissection, per-
foration, acute occlusion, renal parenchymal infarction, or
renal parenchymal perforation. Access site complication
was defined as hematoma, pseudoaneurysms, arteriovenous
fistula, or a vessel injury requiring either percutaneous or
open intervention. Systemic complications were any new
cardiac pulmonary infectious or non-renal systemic compli-
cation that required intervention or halted discharge within
24 hours of the procedure. Response in the hypertensive
patient was defined as follows: “cured” patients were nor-
motensive (diastolic blood pressure 90 mm Hg and sys-
tolic blood pressure 140 mm Hg) without medications;
“improved” patients were normotensive (diastolic blood
pressure90mmHg and/or systolic blood pressure140
mm Hg) on the same (or reduced) number of medications
or had a diastolic blood pressure 15 mmHg below baseline
with the same or reduced number of medications. “No
effect” patients had no change or an inability to meet these
criteria for cure or improvement and were considered a
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plasty were defined as follows: “cured” renal function re-
quired a serum creatinine concentration 1.5 mg/dL;
“improvement” in renal function required a 20% reduc-
tion in the serum creatinine concentration; “stable” renal
function required a 20% increase or reduction in the
serum creatinine concentration; “deterioration” in renal
function required a 20% increase in the serum creatinine
concentration.19 Stable renal function and deterioration
were considered treatment failures. Renal-related morbid-
ity was defined as a persistent increase in creatinine20% of
baseline, progression to hemodialysis, death from renal-
related causes.19
Statistical analysis. We performed our analysis on an
“intention-to-treat” basis. Measured values are reported as
percentages or means  one standard deviation. Mann-
Whitney tests were used to test the difference betweenmeans.
Fischer’s or Chi-squared tests were performed to test the
significance between proportions in each group. Survival and
clinical benefit rates are calculated using life table analysis and
reportedusing the SVS criteria. Standard errors are reported in
actuarial analyses. The log rank test was used to determine
differences between life tables. Non-parametric testing or 2
were used to analyze individual variables. Cox proportional
hazardsmodels were employed for time-dependent outcomes
by preprocedural variables (demographic and comorbidities as
one set and renal anatomic and function variables as a second
set) and periprocedural variables. Analyses were performed
using JMP software version 7.0 (SAS Institute, Cary North
Carolina, USA).
RESULTS
Patient population. Five hundred ninety-two renal ar-
tery interventions were performed in 427 patients. Over the
18 year period, the number of percutaneous interventions did
Table I. Patients characteristics, presenting symptoms
and comorbidities
No MetS MetS P value
Demographics
Patients 205 222 –
Kidneys treated 282 310 –
Male 65% 50% .04
Average age (mean  SD,
years) 70  11 70  9 .99
Symptoms
Hypertension 60% 58% .88
Elevated creatinine 12% 10% .82
Hypertension with elevated
creatinine 28% 32% .64
Comorbidities
Smoking history 84% 64% .002
Coronary artery disease 48% 61% .08
Congestive heart failure 33% 31% .87
Diabetes mellitus 12% 47% .0001
Hyperlipidemia 51% 85% .0001
Cerebrovascular 24% 27% .74rise, and annual volume was maintained over the last 5 years.Fifty-two percent were identified as having MetS. Patients
with MetS were more often female (35% vs 50%, NoMetS vs
MetS). There were no significant differences in presenting
symptoms with the majority in both groups presenting with
hypertension (Table I). More patients with MetS carried a
diagnosis of diabetes and hyperlipidemia butwere less likely to
have a smoking history (Table I). Fifty-six percent of NoMetS
patients and 83% of MetS patients received statins. Other mea-
sured comorbidities were equivalent. There was no significant
difference in the distribution of stage of chronic kidney
disease, mean creatinine concentration, or mean eGFR
between the groups. However, the size, nephrosclerosis
grade, and resistive index of the ipsilateral kidneys were
significantly different between the patients with or without
MetS (Table II). In contrast, the size of the kidney, nephro-
sclerosis grade, and resistive index of the contralateral kid-
neys were not different between the patients with or with-
out MetS (Table II). The anatomy of the contralateral
kidney was equivalent with regard to the presence of disease
Table II. Kidney disease, creatinine levels, eGFR, and
ipsilateral and contralateral hemodynamic and anatomy
parameters
No MetS MetS P value
Kidney disease stage
1 2% 5% .17
2 15% 17%
3 54% 54%
4 21% 19%
5 8% 5%
Functional parameters
Creatinine (mg/dL) 1.7  1.1 1.7  1.0 .99
Mean eGFR mL/min/
1.73 m2 52  28 48  22 .052
eGFR 30 mL/min/
1.73 m2 17% 22% –
eGFR 30-60 mL/min/
1.73 m2 54% 54% .19
eGFR 60 mL/min/
1.73 m2 29% 24% –
Ipsilateral kidney anatomy
Kidney size 10.2  1.4 10.4  1.3 .0001
Resistive index 0.81  0.09 0.77  0.18 .0008
Mean nephrosclerosis
grade 1.32  0.51 1.33  0.51 .0044
Grade 1 70% 68%
.0005
Grade 2 28% 30%
Grade 3 2% 2%
Contralateral kidney
anatomy
Normal 53% 55% .27
Stenosis (60%) 33% 26%
Non-functioning 12% 15%
Surgically absent 2% 3%
Contralateral kidney
parameters
Kidney size 9.8  1.4 9.9  1.4 .99
Resistive index 0.78  0.08 0.77  0.15 .32
Mean nephrosclerosis
grade 1.47  0.71 1.44  0.64
.59
eGFR, Estimated glomerular filtration rate.and functionality (Table II).
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perioperativemortality and equivalentmorbidity (6% vs 7%,
NoMetS vsMetS). The categories of morbidity were similar
between the two groups (Table III). Technical success was
equivalent between the two groups. Those in the NoMetS
group had significantly more predilations than the MetS
group (Table III). However, there was no difference in the
preoperative degree of stenosis between the groups. Stent
placement occurred significantly more frequently in the
MetS group (Table III). Importantly, similar numbers of
contralateral stenoses were treated (Table III). Fifty per-
cent of the NoMetS patients and 47% of the MetS patients
demonstrated “improved” or “cured” hypertension within
3months of intervention (Table IV). Twenty-six percent of
the NoMetS patients and 7% of the MetS patients demon-
strated “improved” or “cured” renal function within 3
months of intervention (Table IV). A similar proportion of
patients in both groups demonstrated no change in renal
function (Table IV). Equivalent numbers in both groups
showed postprocedural functional deterioration (Table
IV).
There were no factors that distinguished those patients
who had cure or improved benefit and those who had
Table III. Interventions
No MetS MetS P value
Interventions
Angioplasty 54% 48% .15
Predilation 38% 28% .01
Stent placement 71% 80% .01
Contralateral intervention 33% 37% .29
Complications
Acute functional injury 20% 18% .98
Anatomic injury 4% 2% .15
Access site 7% 10% .21
Systemic 7% 9% .39
Table IV. Outcomes
No MetS MetS P value
Immediate hypertension outcomes
Deterioration 1% 0% .74
No change 49% 53%
Improved 45% 42%
Cured 5% 5%
Long term hypertension outcomes
Deterioration 6% 10% .29
No change 94% 90%
Immediate renal outcomes
Deterioration 18% 19% .025
No change 63% 75%
Improved 22% 8%
Cured 4% 1%
Long term renal outcomes
Increase in creatinine 9% 14% .27
Progression to hemodialysis 3% 13% .009
Death from renal cause 1% 4% .17deterioration in the No MetS or MetS groups.Outcomes (>3 months). Patient survival was equiv-
alent between the two groups at five years (survival 67% 
4% vs 67%  4%, NoMetS vs MetS) but diverged by 10
years, with survival being 46%  7% vs 34%  8% for
NoMetS andMetS groups, respectively (Fig,A). Survival in
MetSwas influencedby eGFR30mL(RelativeRisk [RR]
2.01, 1.07-3.95; P  .03). There was no significant differ-
ence in the distribution of DM between those that died and
those that survived (Fisher’s exact test two-sided P .154).
Cumulative patency was equivalent between the 2 groups,
but the freedom from restenosis in the MetS group was
significantly lower by life table analysis within 3 years and
continued to diverge thereafter (87% 2% vs 69% 9% at
5 years, NoMetS vs MetS; P  .01) (Fig, B and C). A
greater number of reinterventions were performed tomain-
tain patency in the MetS group. Smoking (RR 1.42, P
.02) and an immediate increase in creatinine (RR  1.58,
1.08-2.25; P .017) influenced restenosis in MetS. There
was no difference in the postoperative degree of stenosis
between the groups, and the final technical result did not
influence the development of restenosis. The presence of
diabetes, the presence of hyperlipidemia, placement of a
stent, or statin administration did not influence restenosis
rates. While freedom from recurrent hypertension was not
significant at 5 years, the MetS group did show a lower
freedom from recurrent hypertension in the long term
(Table IV and Fig, D). When renal-related morbidity was
examined, the MetS group performed significantly worse
within three years and continued to diverge as follow up
continued (retained clinical benefit at five years, 71%  8%
vs 45%  8%, NoMetS vs MetS; P  .01) (Fig, E). The
principal reason for this divergence was a progression to
dialysis (3% vs 13%, NoMetS vs MetS; P  .009) (Table
IV). Smoking (RR  1.54, P  .004) and increasing age
(RR  1.25, P  .001) influenced freedom from renal-
relatedmorbidity. The presence of diabetes, the presence of
hyperlipidemia, placement of a stent, or statin administra-
tion had no influence on the freedom from renal-related
morbidity in the MetS group. No parameter of renal func-
tion or anatomy influenced freedom from renal-related
morbidity in the MetS group. No individual characteristic
of MetS independently influenced patency, restenosis, or
functional outcomes.
When controlled for gender, diabetes, or hyperlidemia,
the effect of the presence of MetS is maintained. There was
no significant difference in outcomes between the first 9
years and the last 9 years of the study.
DISCUSSION
General. This is the first study to examine MetS in
patients undergoing renal intervention. The current study
demonstrates that MetS is present in over 50% of patients
presenting for renal intervention and that it is more com-
mon in females and is associated with significantly poor
markers of renal perfusion before intervention. Periopera-
tive events are not impacted by MetS, but MetS does
adversely affect the long-term anatomic and functional
renal outcomes.
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April 2010930 Davies et alFig. (A) Survival: Kaplan-Meier analysis of survival of the patients with and without MetS. (B) Patency: Kaplan-Meier
analysis of cumulative vessel patency with and without MetS. (C) Restenosis: Kaplan-Meier analysis of freedom from
restenosis of the patients with and without MetS. (D) Hypertension: Kaplan-Meier analysis of freedom from recurrent
hypertension of the patients with and without MetS. (E) Renal-related morbidity: Kaplan-Meier analysis of freedom from
renal-related morbidity (persistent increase in creatinine 20% of baseline, progression to hemodialysis, death from
renal-related causes) of the patients with and without MetS. The number at risk at each time interval is shown below each
figure. Values are mean standard error of the mean. Standard errors exceeding 10% are not shown.
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move away from a strategy based on management of a
single risk factor to one that focuses on a constellation of
synergistic risk factors.20 However, there are multiple def-
initions of MetS,15,21-25 and several substitute abdominal
obesity with a BMI 30 kg/m2. Due to the retrospective
design of our study, we could not obtain the abdominal
circumference of each individual patient, as it is not rou-
tinely determined, and thus used the BMI as a surrogate for
waist circumference. Most of the basic components of the
MetS, namely type 2 diabetes mellitus, hypertension, obesity,
or low high-density lipoprotein cholesterol levels, apart from
being major risk factors for cardiovascular disease, have
been also associated with an increased risk of chronic kidney
disease. Insulin resistance and compensatory hyperinsulin-
emia are independently associated with an increased prev-
alence of chronic kidney disease.26 Multiple observational
studies have consistently shown that increased BMI as well
as insulin resistance and increased fasting insulin levels are
associated with chronic kidney disease, even after adjust-
ment for related disorders.26 Obesity may promote intra-
cellular lipid accumulation in the kidney.27 Prevalence of a
BMI of at least 35 kg/m2 among incident dialysis patients
has increased by 64% over the past decade, and if trends
continue, 20% of all patients will initiate dialysis with this
degree of obesity. Weight loss improves glomerular hemo-
dynamics in morbidly obese adults and may retard progres-
sion of chronic kidney disease. In contrast, once a patient
reaches end-stage renal disease, the degree of adiposity
correlates with survival, and weight loss may not necessarily
be beneficial.28
Patients. In this cohort of patients presenting with
symptomatic renal artery disease, we found MetS was
highly prevalent (52%) and was more common in females.
It has been demonstrated that MetS is present at an equiv-
alent level in patients presenting with lower extremity dis-
ease.29 Well-established indicators of increased cardiovas-
cular risk such as low ankle-brachial index (ABI) and
increased C-reactive protein (CRP) levels also cluster with
MetS.29 The degree of peripheral arterial disease clinical
manifestations was not related to MetS score (ie, the num-
ber of criteria of MetS present).30 We did observe that
patients with MetS and ipsilateral renal artery disease had
anatomic markers of more distal renal disease, while the
contralateral kidneys were normal. This may suggest that
significant renal artery atherosclerosis and MetS act syner-
gistically. A similar observation was made by Wei et al,
where they noted that female patients with MetS and lower
extremity atherosclerosis were more likely to have devel-
oped kidney dysfunction.13 We did see more female pa-
tients in the MetS group, but gender did not emerge as a
significant co-factor during our analysis. Renal artery ste-
nosis is an independent predictor of mortality. At 7 years,
73% of patients with untreated renal artery stenosis are
dead.31 The 7-year actuarial mortality in this study for
patients with MetS was 47% and without MetS was 42%,
which is better than the historically reported data for un-
treated disease. Similar to the current study, immediate andlong-term post procedure creatinine deterioration and di-
alysis dependency have been associated with increasedmor-
tality.16-18 The presence of MetS did appear to alter the
survival after renal intervention.
Anatomic outcomes. While technical success was
equal in both groups, there was a greater use of stents in the
MetS group, which may have reflected more significant
disease. Regardless of the modality chosen to intervene
(angioplasty or stenting), cumulative patency was equiva-
lent between the patients with and without MetS. How-
ever, the freedom from restenosis in the MetS group was
significantly lower by life table analysis within 3 years and
continued to diverge thereafter. This restenosis was not
mirrored by an increase in ipsilateral reintervention rates. It
is possible that the increased restenosis rate was an artifact
induced by the increased use of stents in the MetS group.
In-stent velocities on duplex imaging are considered ele-
vated compared with nonstented vessels. Similarly, target
lesion revascularization in the coronary circulation is not
influenced by the presence of MetS.32,33 Major and minor
morbidity in this study was also equivalent. This is also the
case in the coronary32,33 and carotid circulations following
intervention.14
Functional outcomes. Functional outcomes remain
the primary goal of renal interventions. There is significant
controversy as to whether intervention is superior to best
medical therapy. The most significant finding in this study
is the markedly poor freedom from renal-related morbidity
in MetS. The response in the hypertensive was an equiva-
lent in both groups. Twenty-six percent of the NoMetS
patients and 7% of the MetS patients demonstrated “im-
proved” or “cured” renal function within 3 months of
intervention. This difference in improvement likely reflects
the preexisting anatomic and parenchymal parameters we
noted in the ipsilateral kidney pre-intervention. During
long-term follow up, despite normal mean eGFR and dis-
tribution of chronic kidney disease, more patients demon-
strated progression to hemodialysis in the MetS group.
MetS appears to be a risk factor for chronic kidney disease,
likely due to the combination of dys-glycemia and high
blood pressure.5 Ispilateral kidneys in the MetS group
showed a decrease in length, resistive index, and nephro-
sclerosis grade compared with those in the NoMetS group,
suggesting parenchymal deterioration. However, the con-
tralateral kidneys were equivalent between the two groups,
suggesting that MetS on its own was unlikely to have
induced the changes in parenchymal parameters.
CONCLUSION
MetS is prevalent among patients undergoing renal
angioplasty and stenting. MetS is associated with mark-
edly reduced renal clinical benefit and increased progres-
sion to hemodialysis following endovascular intervention
for atherosclerotic renal artery stenosis. MetS is thus a
risk factor for poor long-term outcomes following renal
interventions.
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